RenovoRx, Inc.
RNXT· Nasdaq
Released Nov 13, 2025, after the close
10-Q filed Nov 13, 2025, 44 days after period end · 0001493152-25-022304
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $266.00K | — | — | — |
| Net Income | -$2.91M | -$2.47M | -$1.42M | -$2.14M |
| EPS Diluted |
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.10 |
| -$0.13 |
| -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.